Application of linoleic acid in preparation of medicine for improving sensitivity of gram-positive bacteria to antibiotics
By combining linoleic acid with antibiotics, a compound preparation was prepared, which solved the problem of drug resistance in Gram-positive bacteria, improved the sensitivity and clearance of antibiotics, and prolonged the effect of antibiotics. This preparation can be applied to the preparation of anti-infective drugs.
Patent Information
- Application Number
- CN202411031248.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-30
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2044-07-30
AI Technical Summary
Gram-positive bacteria develop resistance to existing antibiotics, making the development of new antibacterial drugs difficult and limiting treatment effectiveness.
Linoleic acid is used in combination with antibiotics to prepare drugs that improve the antibiotic sensitivity of Gram-positive bacteria, including compound preparations of cephalosporins, aminoglycosides, quinolones, tetracyclines, carbapenems, glycopeptides, macrolides, sulfonamides, and penicillins.
It significantly improves the sensitivity of Gram-positive bacteria to antibiotics, enhances the body's survival rate and clearance ability against infection, prolongs the after-effect of antibiotics, and has high safety, making it widely used in food and pharmaceuticals.
Smart Images

Figure CN118903092A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biomedicine technology, and more specifically, relates to the application of linoleic acid in the preparation of a drug for improving the sensitivity of Gram-positive bacteria to antibiotics. Background Art
[0002] Staphylococcus aureus (Staphylococcus aureus Rosenbach) is a common clinical pathogen that often causes community and hospital infections, and the infections caused by it are the second most common, second only to Escherichia coli. Reasonable antibiotic intervention is still an effective means of treating S. aureus infections. β-lactam drugs represented by penicillin and cephalosporin are one of the important drugs for the clinical treatment of S. aureus infections. However, due to the widespread use of β-lactam drugs in clinical practice, especially the increase in the detection rate of methicillin-resistant Staphylococcus aureus (MRSA), it presents the characteristics of multidrug resistance to antimicrobial drugs, resulting in the clinical efficacy of β-lactam drugs being greatly limited.
[0003] Therefore, in the current situation where the drug resistance of Gram-positive bacteria including MRSA is becoming increasingly serious and the research and development of new antimicrobial drugs is becoming increasingly difficult, finding effective antimicrobial enhancers and restoring the sensitivity of multidrug-resistant bacteria including MRSA to existing key antimicrobial drugs through reasonable combination drug strategies are of great significance for improving the clinical efficacy of antimicrobial drugs and delaying the development of drug resistance. Summary of the invention
[0004] The technical problem to be solved by the present invention is to overcome the defects and shortcomings that Gram-positive bacteria have developed resistance to existing antibiotics and that the research and development of new antibacterial drugs is increasingly difficult, and to provide the use of linoleic acid in the preparation of antibiotic enhancers. The antibiotics can not only improve the survival rate of the body against infected Gram-positive bacteria, but also improve the body's ability to eliminate Gram-positive bacteria.
[0005] The purpose of the present invention is to provide an application of linoleic acid in combination with antibiotics in the preparation of a drug for improving the sensitivity of Gram-positive bacteria to antibiotics.
[0006] Another object of the present invention is to provide the use of linoleic acid in combination with antibiotics in the preparation of a drug for preventing and / or treating Gram-positive bacterial infection.
[0007] Another object of the present invention is to provide a drug for improving the sensitivity of Gram-positive bacteria to antibiotics.
[0008] The above-mentioned purpose of the present invention is achieved through the following technical solutions:
[0009] The invention discloses an application of protected linoleic acid in the preparation of an antibiotic synergist, wherein the antibiotic is selected from cephalosporins, aminoglycosides, quinolones, tetracyclines, carbapenems, glycopeptides, macrolides, sulfonamides, penicillins or pharmaceutically acceptable salts thereof, or a compound preparation containing one or more of the antibiotics; and the penicillins do not include ampicillin.
[0010] Linoleic acid is an important unsaturated fatty acid and an essential fatty acid for the human body. It has the effects of lowering cholesterol, softening blood vessels, and promoting microcirculation, and can prevent the occurrence of various cardiovascular and cerebrovascular diseases. The inventor team discovered for the first time that the combination of linoleic acid and the above-mentioned antibiotics can significantly improve the sensitivity of Gram-positive bacteria to antibiotics; in vivo research data show that the combination of linoleic acid and the above-mentioned antibiotics (such as cefoperazone sodium and sulbactam sodium) can not only improve the survival rate of the body against Gram-positive bacteria, but also improve the body's ability to clear Gram-positive bacteria. Linoleic acid + antibiotics are prepared into an anti-infection composition, which can achieve significant clinical anti-infection effects on the one hand, and on the other hand, can prolong the post-effect of antibiotics (the post-effect of antibiotics (PAE) refers to the effect that the inhibitory effect on microorganisms still maintains a period of time after the bacteria are exposed to antibiotics, although the serum concentration of antibiotics drops below the minimum inhibitory concentration or disappears); and linoleic acid is an essential fatty acid in human and animal nutrition, with high nutritional value, and has been widely used in food and medicine, with high safety.
[0011] Furthermore, the linoleic acid increases the sensitivity of Gram-positive bacteria to antibiotics.
[0012] The invention discloses an application of the protected linoleic acid in combination with an antibiotic in the preparation of a drug for improving the sensitivity of Gram-positive bacteria to antibiotics, wherein the antibiotic is selected from cephalosporins, aminoglycosides, quinolones, tetracyclines, carbapenems, glycopeptides, macrolides, sulfonamides, penicillins or their pharmaceutically acceptable salts or a compound preparation containing one or more of the antibiotics; and the penicillins do not include ampicillin.
[0013] The present invention also protects the use of linoleic acid in combination with antibiotics in the preparation of a drug for preventing and / or treating Gram-positive bacterial infections, wherein the antibiotics are selected from cephalosporins, aminoglycosides, quinolones, tetracyclines, carbapenems, glycopeptides, macrolides, sulfonamides, penicillins or their pharmaceutically acceptable salts or a compound preparation containing one or more of the antibiotics; and the penicillins do not include ampicillin.
[0014] Preferably, the antibiotic is selected from cefoperazone sodium and sulbactam sodium (cephalosporins + β-lactamase inhibitor, i.e., a compound preparation), cefotaxime (cephalosporins), cefoperazone (cephalosporins), amikacin (aminoglycoside), tobramycin (aminoglycoside), gentamicin (aminoglycoside), ofloxacin (quinolone), levofloxacin (quinolone), tetracycline (tetracyclines), meropenem (carbapenem), vancomycin (glycopeptide), azithromycin (macrolide), sulfadiazine (sulfonamide) or amoxicillin sodium and clavulanate potassium (penicillin + β-lactamase inhibitor, i.e., a compound preparation).
[0015] Furthermore, the cefoperazone sodium and sulbactam sodium is a composite preparation of cefoperazone and sulbactam, wherein both cefoperazone and sulbactam are in the form of sodium salts; further, in the composite preparation, the mass ratio of cefoperazone to sulbactam is 1:1.
[0016] Furthermore, the amoxicillin sodium clavulanate potassium is a composite preparation of amoxicillin and clavulanic acid, wherein amoxicillin exists in the form of sodium salt, and potassium clavulanate exists in the form of potassium salt; further, in the composite preparation, the mass ratio of amoxicillin to clavulanic acid is (2-7):1.
[0017] Preferably, in the composite preparation, the mass ratio of amoxicillin to clavulanic acid is 2:1, 4:1 or 7:1.
[0018] Furthermore, the Gram-positive bacteria are selected from one or more of Staphylococcus aureus, Streptococcus iniae, Streptococcus agalactiae, Streptococcus pyogenes, Bacillus subtilis, and Enterococcus faecalis.
[0019] Furthermore, the Staphylococcus aureus includes sensitive bacteria and drug-resistant bacteria.
[0020] Furthermore, the sensitive bacteria is Methicillin-Sensitive Staphylococcus Aureus (MSSA), and the resistant bacteria is Methicillin-Resistant Staphylococcus Aureus (MRSA).
[0021] Furthermore, the linoleic acid acts as an antibiotic synergist to enhance the ability of antibiotics to kill Gram-positive bacteria.
[0022] Furthermore, the linoleic acid acts as an antibiotic synergist to enhance the ability of antibiotics to eliminate Gram-positive bacteria.
[0023] Furthermore, the linoleic acid acts as an antibiotic synergist to enhance the body's resistance to infection with Gram-positive bacteria.
[0024] Furthermore, the linoleic acid acts as an antibiotic synergist to increase the amount of antibiotics entering cells. Exogenous addition of linoleic acid can increase the permeability of the bacterial membrane of Gram-positive bacteria, thereby increasing the amount of antibiotics entering cells, thereby promoting the sensitivity of bacteria to antibiotics.
[0025] Furthermore, the linoleic acid acts as an antibiotic synergist to delay the post-effect of Gram-positive bacteria on antibiotics.
[0026] Furthermore, the linoleic acid acts as an antibiotic synergist to delay the after-effects of Gram-positive bacteria on cefoperazone sodium and sulbactam sodium.
[0027] The present invention also protects a drug for increasing the sensitivity of Gram-positive bacteria to antibiotics, comprising an effective amount of linoleic acid and an antibiotic; the antibiotic is selected from cephalosporins, aminoglycosides, quinolones, tetracyclines, carbapenems, glycopeptides, macrolides, sulfonamides, penicillins or their pharmaceutically acceptable salts or a compound preparation containing one or more of the antibiotics; and the penicillins do not include ampicillin.
[0028] Preferably, the mixing ratio of linoleic acid to antibiotics is 1: (2-40000) g / mol. This mixing ratio means that 2-40000 g of antibiotics are used in combination with 1 mol of linoleic acid.
[0029] More preferably, the mixing ratio of linoleic acid to antibiotic is 1: (50-40000) g / mol.
[0030] Compared with the prior art, the present invention has the following beneficial effects: the present invention discovers for the first time that the combination of linoleic acid and antibiotics significantly improves the sensitivity of Gram-positive bacteria to antibiotics; in vivo research data show that the combination of linoleic acid and antibiotics can not only improve the survival rate of mice infected with Gram-positive bacteria, but also improve the ability of mice to eliminate Gram-positive bacteria; further, linoleic acid and antibiotics are prepared into an anti-infection composition, which can achieve a significant clinical anti-infection effect on the one hand, and prolong the clinical effect of antibiotics on the other hand; and linoleic acid is an essential fatty acid in human and animal nutrition, has high nutritional value, has been widely used in food and medicine, and has high safety. BRIEF DESCRIPTION OF THE DRAWINGS
[0031] Figure 1 This is a diagram of the PCR amplification results of clinical Staphylococcus aureus genes in Example 1.
[0032] Figure 2The statistical graphs show the results of linoleic acid killing clinical Staphylococcus aureus sensitive bacteria MSSA 2 (A) and drug-resistant bacteria MRSA7 (B) in Example 2, as well as the bactericidal effect having a linoleic acid concentration effect.
[0033] Figure 3 The results of the statistical diagram of the time effect of linoleic acid in killing clinical Staphylococcus aureus MRSA 7 (A) and MSSA 2 (B) in Example 2 are shown.
[0034] Figure 4 This is a statistical chart showing the results of linoleic acid killing multiple strains of clinical Staphylococcus aureus sensitive bacteria (A) and resistant bacteria (B) in Example 2.
[0035] Figure 5 This is a statistical graph showing the results of Example 3 showing that linoleic acid can improve the survival rate (A) and clearance ability (B) of mice infected with clinical Staphylococcus aureus.
[0036] Figure 6 This is a statistical diagram showing the results that linoleic acid can improve the sensitivity of clinical Staphylococcus aureus (A) and other Gram-positive bacteria (B) to cefoperazone sodium and sulbactam sodium, and can improve the sensitivity of Staphylococcus aureus to other antibiotics (C) in Example 4.
[0037] Figure 7 The results of Example 5 are statistical graphs showing the effects of linoleic acid concentration (A), antibiotic concentration (B) and time gradient (C) on linoleic acid improving the sensitivity of clinical Staphylococcus aureus to cefoperazone sodium and sulbactam sodium.
[0038] Figure 8 This is a statistical graph showing the results of Example 6 showing that linoleic acid synergistically with cefoperazone sodium and sulbactam sodium can improve the survival rate (A) and clearance ability (B) of mice infected with clinical Staphylococcus aureus.
[0039] Fig. 9 This is a statistical graph showing the results of improving the permeability of clinical Staphylococcus aureus sensitive bacteria MSSA (A) and resistant bacteria MRSA (B) after adding linoleic acid in Example 7.
[0040] Fig.10 This is a statistical chart showing the results of increasing the antibiotic content entering clinical Staphylococcus aureus after adding linoleic acid in Example 7.
[0041] Fig.11 This is a statistical chart showing the results of Example 8 in which linoleic acid can delay the post-effects of clinical Staphylococcus aureus on cefoperazone sodium and sulbactam sodium. DETAILED DESCRIPTION
[0042] The present invention is further described below in conjunction with the accompanying drawings and specific examples, but the examples do not limit the present invention in any form. Unless otherwise specified, the reagents, methods and equipment used in the present invention are conventional reagents, methods and equipment in the art.
[0043] Unless otherwise specified, the reagents and materials used in the following examples are commercially available.
[0044] Example 1 Analysis of clinical antibiotic resistance of Staphylococcus aureus
[0045] Nine strains of sensitive Staphylococcu saureus (MSSA) and 20 strains of methicillin-resistant Staphylococcu saureus (MRSA) obtained from clinical practice were named MSSA 1-9 and MRSA 1-20.
[0046] 1.1 Determination of drug resistance of clinical strains
[0047] Twenty-nine clinical Staphylococcus aureus strains were cultured overnight, and the bacteria were cultured to OD600 of 0.5 after 1:100 transfer. Then, after 100-fold dilution, the minimum inhibitory concentration (MIC) of these strains to daptomycin (DAP), vancomycin (VAN), cefoperazone sodium and sulbactam sodium (SCF) and oxacillin (OX) was determined according to the microbial susceptibility test protocol provided by the Clinical and Laboratory Standards Institute (CLSI). The results are shown in Table 1.
[0048] Table 1 Minimum inhibitory concentration (MIC) of four antibiotics against 29 strains of Staphylococcus aureus
[0049]
[0050] Note: For OX, MIC≤2 means sensitive bacteria; for DAP: MIC≤1 means sensitive bacteria; for VAN: MIC≤2 means sensitive bacteria.
[0051] As shown in Table 1, the above 20 MRSA strains are all resistant to the 4 antibiotics tested, which also shows that these 20 strains are not only methicillin-resistant bacteria, but also multidrug-resistant bacteria (Table A in Table 1), while 9 MRSA strains are sensitive to all 4 antibiotics (Table B in Table 1).
[0052] 1.2 Genetic identification of clinical strains
[0053] femB (651 bp) is an intrinsic gene of Staphylococcus aureus, mecA (310 bp) is a unique gene of methicillin-resistant strains, and PVL is an exotoxin produced by Staphylococcus aureus - leukocidin, which damages the body's defense barrier and immune response by destroying white blood cells and phagocytes.
[0054] Clinical strains were cultured overnight, and the three genes of each strain were amplified by colony PCR (the sequences of amplification primers are shown in Table 2), and then the amplification products were detected by gel electrophoresis. Figure 1 As can be seen from the figure, for MRSA strains, each resistant strain can amplify these three genes, indicating that they are indeed Staphylococcus aureus, and are methicillin-resistant strains, and are all toxic. For sensitive strains, each strain can amplify femB, but not mecA, indicating that these strains are indeed Staphylococcus aureus and sensitive bacteria. However, some strains have exotoxin genes, while others do not.
[0055] Table 2 Primer sequences
[0056]
[0057] Example 2 Linoleic acid can kill Staphylococcus aureus from clinical sources
[0058] 2.1 Preparation of strain samples
[0059] A single colony of clinical bacteria was picked from the solid LB plate, inoculated into 5 mL LB liquid medium, and cultured at 37°C and 200 rpm for 16 h; the bacterial liquid was collected, centrifuged at 8000 rpm for 5 min, the supernatant was removed, and the bacteria were washed with an equal volume of 0.85% saline, and finally 1×M9 basic medium (containing 10 mM acetate, 1 M CaCl 2 ) Suspend the bacteria; adjust the OD value of the bacterial solution to 0.2 and dispense 5 mL into test tubes for subsequent experiments.
[0060] 2.2 Linoleic acid can kill clinical Staphylococcus aureus and has a linoleic acid concentration gradient effect
[0061] Prepare samples of clinically sensitive strain MSSA 2 and clinically resistant strain MRSA 7 according to 2.1 in Example 2. Add linoleic acid to the test tubes to give final concentrations of 0, 0.01, 0.05, 0.1, 0.5, 1, 5 and 10 mM, respectively. Perform 3 biological replicates for each concentration. Cultivate at 37°C and 200 rpm for 10 hours, use a plate to detect the number of viable bacteria, and then calculate the survival rate of bacteria at different linoleic acid concentrations. The calculation formula is: Survival rate (%) = (number of viable bacteria after adding linoleic acid / number of viable bacteria without adding linoleic acid) × 100%. See the results. Figure 2A. As can be seen from the figure, whether it is sensitive bacteria or resistant bacteria, the survival rate of bacteria is significantly reduced after adding linoleic acid. And as the concentration of linoleic acid increases, the bactericidal efficiency gradually increases. The specific situation is:
[0062] For clinically sensitive bacteria MSSA 2 (such as Figure 2 As shown in Figure A in the figure, when 0.01mM linoleic acid is added, it can play a better killing effect, and the bactericidal effect is increased by 8.07 times compared with the control group (the survival rate dropped to 12.39%); when the concentration of linoleic acid gradually increases from 0.05mM to 10mM, the bactericidal efficiency increases by 19.91 times, 129.58 times, 709.17 times, 1925.93 times, 4681.57 times and 9577.32 times respectively (the survival rate also drops from 5.02% to 0.01%).
[0063] For clinical drug-resistant bacteria MRSA 7 (such as Figure 2 When the concentration of linoleic acid was 0.01 mM, the bactericidal effect was 7.14 times higher than that of the control group (the survival rate dropped to 14.00%). Similarly, when the concentration of linoleic acid gradually increased from 0.05 mM to 10 mM, the bactericidal efficiency increased by 15 times, 39.47 times, 230.77 times, 1257.24 times, 2675.16 times and 4199.48 times respectively (the survival rate also dropped from 6.67% to 0.02%).
[0064] Among them, when the concentration of linoleic acid was 1mM, the bactericidal efficiency of sensitive bacteria and resistant bacteria increased by 1925.93 times and 1257.24 times respectively. As the concentration of linoleic acid increased, the bactericidal multiple also increased. However, since linoleic acid is acidic, when the amount added is too high, it will affect the pH value of the incubation system. Therefore, 1mM linoleic acid was selected for subsequent research in the subsequent experiments.
[0065] This result shows that linoleic acid can kill Staphylococcus aureus from clinical sources, including sensitive strains and resistant strains, and has a linoleic acid concentration gradient effect.
[0066] 2.3 Linoleic acid kills clinical Staphylococcus aureus in a time-dependent manner
[0067] According to 2.1 of Example 2, MSSA 2 and MRSA 7 samples were prepared, 1 mM linoleic acid was added to the test tubes respectively, and no linoleic acid was used as a control. The live bacteria were counted on the plate at different times, and the survival rate was calculated to study the relationship between the bactericidal efficiency and time.
[0068] The results are as follows Figure 3As shown in the figure, it can be seen that after adding linoleic acid, the bacterial count of clinical bacteria MSSA 2 and MRSA7 did not decrease within 2 hours, and then the bacterial count decreased significantly as time went on, showing a time effect. The specific situation is as follows:
[0069] For MRSA 7( Figure 3 For example, in Figure A, the number of bacteria decreased by 15 times in 4 hours, and the number of bacteria decreased by 137.67-13641.57 times in 6-12 hours. Figure 3 For example, in Figure B, the number of bacteria decreased by 12.8 times in 4 hours, and the reduction in the number of bacteria was 216.15-16818.73 times in 6-12 hours.
[0070] The above results show that linoleic acid has a time-dependent effect on killing clinical Staphylococcus aureus. Linoleic acid can achieve a good killing effect on clinical Staphylococcus aureus in 10 hours. For ease of operation, subsequent experiments will use 10 hours as the bactericidal time of linoleic acid for research.
[0071] 2.4 Linoleic acid is widely used to kill Staphylococcus aureus in clinical practice
[0072] The remaining 8 strains of sensitive bacteria and 19 strains of resistant bacteria were prepared according to 2.1 in Example 2. Each bacterial strain was divided into 2 groups, namely, M9 control group and 1mM linoleic acid test group. After incubation at 37°C and 200rpm for 10 hours, the viable bacteria were counted, and the survival rate of each strain after adding linoleic acid was calculated. Three biological replicates were performed for each strain.
[0073] Results Figure 4 As can be seen from the figure, linoleic acid can kill all clinically sensitive bacteria and drug-resistant bacteria, but the degree of improving sensitivity is different for different strains, as described below:
[0074] To 8 sensitive bacteria ( Figure 4 (Figure A in the figure), except for the MSSA1 strain, the bactericidal multiple after adding linoleic acid was only 81.97 times, the bactericidal multiples of the other strains were between 1925.93 and 98846.78 times.
[0075] For 19 drug-resistant strains ( Figure 4 Figure B), the sterilization multiples ranged from 7.39 to 14918.69. Among them, 3 strains had a sterilization multiple lower than 100 times, namely strains 11, 12 and 15; 5 strains had a sterilization multiple greater than 100 but less than 1000 times, namely strains 8, 13, 14, 16 and 17; the rest had a sterilization multiple greater than 1000 times, namely strains 1-6, 9, 10, 18-20.
[0076] Example 3 Linoleic acid can improve the resistance of mice to clinical Staphylococcus aureus infection 3.1 Linoleic acid can improve the survival rate of mice to clinical Staphylococcus aureus infection
[0077] Balb / c mice (6-8 weeks, about 20 g, half male and half female) were divided into three groups, 16 mice in each group, namely, normal saline control group, antibiotic treatment group and linoleic acid test group. The challenge strain was the drug-resistant MRSA7, and the infection dose was 1.2×10 8 CFU was measured by intraperitoneal injection. One hour after bacterial infection, mice in the treatment group were given cefoperazone sodium and sulbactam sodium by intravenous injection at a dose of 200 mg / kg; mice in the experimental group were given linoleic acid by intraperitoneal injection at a dose of 100 mg / kg. The death of mice was observed and recorded daily, and the survival rate of each group was calculated every day for a total of 7 days. The calculation formula is: survival rate = number of surviving mice in each group / total number of mice in each group × 100%.
[0078] The experimental results are shown in Figure 5 Figure A shows that in the saline control group, 68% died on the first day and all died on the second day; in the antibiotic treatment group, 31% died on the first day and 62% died on the second day, and then no more died, with a survival rate of 7%; in the linoleic acid experimental group, no one died on the first day, 7% died on the second day, and then stabilized, no more died, and the survival rate was 93%. Compared with the control group, the protection rate of mice injected with linoleic acid increased by 93%, and compared with the antibiotic treatment group, the protection rate of mice injected with linoleic acid increased by 86%.
[0079] The results show that when mice are infected with methicillin-resistant bacteria, when antibiotic treatment is basically ineffective, linoleic acid can significantly improve the mice's resistance to methicillin-resistant bacteria infection.
[0080] 3.2 Linoleic acid can improve the clearance of clinical Staphylococcus aureus infection in mice
[0081] Balb / c mice (6-8 weeks, about 20 grams, half male and half female) were divided into two groups, 6 in each group, a control group and a linoleic acid test group. The challenge strain was methicillin-resistant Staphylococcus aureus MRSA7, and the infection dose was 1.4×10 6 CFU was measured by intraperitoneal injection. One hour after bacterial infection, linoleic acid was intraperitoneally administered at a dose of 100 mg / kg. Six hours later, equal weight of internal organs (liver, spleen, kidney) were taken and fully ground, then diluted and plated to count the number of bacteria in the organs.
[0082] Results Figure 5As shown in Figure B, when mice were infected with drug-resistant bacteria, if linoleic acid was given to treat them, the bacterial load in the spleen, kidney and liver of the mice decreased by 1563 times, 1009 times and 4419 times respectively. The results show that linoleic acid can significantly improve the clearance of clinical Staphylococcus aureus infection in mice.
[0083] Example 4 Linoleic acid can increase the sensitivity of Gram-positive bacteria to antibiotics
[0084] 4.1 Linoleic acid can improve the sensitivity of clinical Staphylococcus aureus to cefoperazone sodium and sulbactam sodium
[0085] The results of 2.4 in Example 2 show that linoleic acid has a killing effect on Staphylococcus aureus of clinical origin. However, it was also found that the bactericidal effects of different strains were different, and some of the strains had a killing effect of less than 1000 times. In view of the fact that bacterial infections are still treated with antibiotics, can linoleic acid cooperate with antibiotics to improve the sensitivity of strains to antibiotics? For this reason, all strains MRSA8, 11-17 and MSSA1 with a bactericidal effect of linoleic acid less than 1000 times in 2.4 in Example 2 were selected, and strains MSSA2, MSSA8, MRSA4, 9, and 18 with a bactericidal multiple of linoleic acid greater than 1000 times were selected, a total of 14 strains of bacteria were used as objects, and linoleic acid was used to cooperate with antibiotics for bactericidal tests.
[0086] The above strain samples were prepared according to 2.1 in Example 2, and each strain was divided into 4 groups: M9 control group, antibiotic group, linoleic acid group, and linoleic acid + antibiotic group. The antibiotics were cefoperazone sodium and sulbactam sodium, and the concentrations used for each strain were shown in Table 3. The concentration of linoleic acid was 1 mM. After incubation at 37°C and 200 rpm for 10 hours, the number of viable bacteria was detected using a plate, and then the survival rate of bacteria in different treatment groups was calculated. The calculation formula was: survival rate (%) = (number of viable bacteria after adding linoleic acid and / or antibiotics / number of viable bacteria in the control group) × 100%.
[0087] Results Figure 6 As shown in Figure A, these strains have no bactericidal effect or very weak bactericidal effect when antibiotics are added alone, and the bactericidal multiple is only between 1.07-2.57 times. However, if linoleic acid is added on the basis of antibiotics, the sensitivity of all strains to antibiotics is significantly improved. For strains with a bactericidal effect of less than 1000 times when linoleic acid is added alone, the bactericidal multiple is further increased by 7.88-282.44 times on the basis of the original single addition of linoleic acid. For strains with a bactericidal effect of more than 1000 times when linoleic acid is added alone, the bactericidal multiple is further increased by 1.35-4 times on the basis of the original single addition of linoleic acid.
[0088] Table 3 Concentration of cefoperazone sodium and sulbactam sodium used in the test strains
[0089]
[0090] 4.2 Linoleic acid can increase the sensitivity of other Gram-positive bacteria to cefoperazone sodium and sulbactam sodium
[0091] Prepare samples of Streptococcus dolphinus, Streptococcus agalactiae, Streptococcus pyogenes, Bacillus subtilis and Enterococcus faecalis according to 2.1 in Example 2. The drug resistance of these bacteria, i.e., MIC determination, is shown in Table 4. Each strain is divided into 4 groups: M9 control group, antibiotic group, linoleic acid group, and linoleic acid + antibiotic group. The antibiotics are cefoperazone sodium and sulbactam sodium, and the concentration used for each strain is: 300ug / mL for Streptococcus dolphinus, 50ug / mL for Streptococcus agalactiae, 400ug / mL for Streptococcus pyogenes, 200ug / mL for Bacillus subtilis, and 400ug / mL for Enterococcus faecalis; the concentration of linoleic acid is 0.01mM. After incubation at 37℃ and 200rpm for 10 hours, the number of viable bacteria was detected by plate, and then the survival rate of bacteria in different treatment groups was calculated. The calculation formula is: survival rate (%) = (number of viable bacteria after adding linoleic acid and / or antibiotics / number of viable bacteria in the control group) × 100%.
[0092] Table 4 Bacterial resistance detection
[0093]
[0094] Note: For Streptococcus dolphinus, Streptococcus agalactiae, and Streptococcus pyogenes: Penicillins ≤0.25 are sensitive, and there are no standards for resistance and intermediate levels; Cephalosporins ≤0.25 are sensitive, and there are no standards for resistance and intermediate levels; Carbapenems ≤0.5 are sensitive, and there are no standards for resistance and intermediate levels; Tetracycline: ≤2 is sensitive, 4 is intermediate, and ≥8 is resistant; Levofloxacin: ≤2 is sensitive, 4 is intermediate, and ≥8 is resistant; Vancomycin ≤1 is sensitive, and there are no standards for resistance and intermediate levels.
[0095] Enterococcus faecalis: Penicillins: ≤8 is sensitive, no reports of intermediate values, and ≥16 is resistant; Tetracyclines: ≤4 is sensitive, 8 is intermediate, and ≥16 is resistant; Levofloxacins: ≤2 is sensitive, 4 is intermediate, and ≥8 is resistant; Vancomycin: ≤4 is sensitive, 8-16 is intermediate, and ≥32 is resistant.
[0096] Bacillus subtilis: Penicillins ≤8 are sensitive, 8-16 are intermediate, and ≥32 are resistant; cephalosporins ≤4 are sensitive, 8 are intermediate, and ≥16 are resistant; Tobramycin ≤4 are sensitive, 8 are intermediate, and ≥16 are resistant; Tetracycline: ≤4 is sensitive, 8 are intermediate, and ≥16 are resistant; Levofloxacin: ≤0.5 is sensitive, 1 is intermediate, and ≥2 is resistant.
[0097] R: resistant; I: intermediate; S: sensitive.
[0098] As can be seen from Table 4, the Gram-positive bacteria listed above are resistant to most of the antibiotics tested and are multidrug-resistant bacteria.
[0099] Depend on Figure 6 As shown in Figure B, these strains had no bactericidal effect or had very weak bactericidal effects when antibiotics were added alone, with the bactericidal multiples ranging from only 1.1 to 1.69 times. However, if linoleic acid was added on the basis of antibiotics, the sensitivity of all strains to antibiotics was significantly improved, and the bactericidal multiples of Streptococcus dolphinus, Streptococcus agalactiae, Streptococcus pyogenes, Bacillus subtilis and Enterococcus faecalis were increased by 315.58 times, 3.71 times, 2254.49 times, 77.45 times and 284.59 times, respectively.
[0100] 4.3 Linoleic acid can improve the sensitivity of clinical Staphylococcus aureus to other antibiotics
[0101] According to 2.1 in Example 2, clinical drug-resistant bacteria MRSA9 samples were prepared and divided into 4 groups: M9 control group, linoleic acid group, antibiotic group, and linoleic acid + antibiotic group. The antibiotic concentrations in the experiment were: vancomycin was 100 micrograms / mL, and the other antibiotics were all 100 micrograms / mL; the linoleic acid concentration was 0.01mM. After incubation at 37°C and 200rpm for 10 hours, the number of viable bacteria was detected using a plate, and then the survival rate of bacteria in different treatment groups was calculated. The calculation formula is: survival rate (%) = (number of viable bacteria after adding linoleic acid and / or antibiotics / number of viable bacteria in the control group) × 100%.
[0102] Results Figure 6 Figure C shows that when only antibiotics are added, the survival rate of bacteria is 67.24-98.27% except for vancomycin, which is 44.82%. When linoleic acid is added alone, the survival rate of bacteria is 70%. However, if the two are used in combination, that is, linoleic acid is added on the basis of antibiotics, except for polymyxin, clindamycin and ampicillin, the sensitivity of the strains to antibiotics is improved by 2.82-2826 times.
[0103] These results indicate that when linoleic acid is used in combination with cefoperazone sodium sulbactam sodium, or other antibiotics such as tetracycline, meropenem, amikacin, levofloxacin, tobramycin, gentamicin, vancomycin, cefotaxime, azithromycin, amoxicillin sodium clavulanate potassium and sulfadiazine, the bactericidal ability of antibiotics against these bacteria is enhanced, indicating that linoleic acid can not only significantly improve the sensitivity of clinical Staphylococcus aureus to cefoperazone sodium sulbactam sodium, but also improve the sensitivity of Gram-positive bacteria such as Streptococcus, Bacillus subtilis and Coprococcus to cefoperazone sodium sulbactam sodium and other antibiotics including tetracycline, meropenem, amikacin, levofloxacin, tobramycin, gentamicin, vancomycin, cefotaxime, azithromycin, amoxicillin sodium clavulanate potassium and sulfadiazine.
[0104] Example 5 Linoleic acid improves the sensitivity of clinical Staphylococcus aureus to cefoperazone sodium and sulbactam sodium, with linoleic acid concentration, antibiotic concentration and time effects
[0105] Taking Staphylococcus aureus as the representative of Gram-positive bacteria and cefoperazone sodium and sulbactam sodium as the representatives of antibiotics, the effect of linoleic acid combined with antibiotics was further explored.
[0106] 5.1 Linoleic acid concentration effect
[0107] According to 2.1 in Example 2, clinical drug-resistant strain MRSA 12 samples were prepared and divided into 7 groups: an antibiotic control group (200 μg / mL cefoperazone sodium and sulbactam sodium), and 6 experimental groups: on the basis of adding 200 μg / mL cefoperazone sodium and sulbactam sodium, linoleic acid was added respectively to make the final concentrations of 0.01, 0.05, 0.1, 0.5, 1 and 5 mM, respectively. Three biological replicates were performed for each concentration. The cells were cultured at 37°C and 200 rpm for 10 hours, and the number of viable bacteria was detected by plate and then converted into Log10 values. A decrease of 1 Log10, i.e. a decrease of 1 order of magnitude, indicates that the number of bacteria has decreased by 10 times, and a decrease of 2 Log10, i.e. a decrease of 2 orders of magnitude, indicates that the number of bacteria has decreased by 100 times. See the results. Figure 7 As shown in Figure A, the number of surviving bacteria decreased after adding linoleic acid on top of antibiotics, and the number of surviving bacteria decreased more significantly as the concentration of linoleic acid increased.
[0108] The specific situation is as follows: When 0.01mM linoleic acid is added to the antibiotics, it can play a better role in improving the sensitivity of antibiotics. Compared with the control group, that is, the number of surviving bacteria is reduced by nearly 0.5 Log, that is, the number of bacteria is reduced by about 5 times. When the concentration of linoleic acid gradually increases from 0.05mM to 5mM, the number of surviving bacteria decreases by 1.32, 1.97, 2.86, 3.28 and 3.73 orders of magnitude, respectively, that is, the number of bacteria is reduced from more than ten times to thousands of times.
[0109] 5.2 Antibiotic concentration effect
[0110] According to 2.1 in Example 2, clinical drug-resistant strain MRSA 12 samples were prepared and divided into 6 groups: a linoleic acid control group (1 mM), and 5 experimental groups: on the basis of adding 1 mM linoleic acid, cefoperazone sodium and sulbactam sodium were added respectively, so that the final concentrations were 10, 50, 100, 200 and 400 μg / mL, respectively. Three biological replicates were performed for each concentration. The cells were cultured at 37°C and 200 rpm for 10 hours, and the number of viable cells was detected by plate, and then converted into Log10 values. The results are shown in Figure 7As shown in Figure B, the number of surviving bacteria decreased after adding antibiotics on the basis of linoleic acid, and the number of surviving bacteria decreased more significantly as the concentration of antibiotics increased.
[0111] The specific situation is as follows: When 10μg / mL of antibiotics is added to linoleic acid, it can play a better role in improving antibiotic sensitivity. Compared with the control group, that is, only linoleic acid is added, the number of surviving bacteria is reduced by 0.59 Log, that is, the number of bacteria is reduced by about 6 times. When the antibiotic concentration is gradually increased from 50μg / mL to 400μg / mL, the number of surviving bacteria decreases by 1.76, 3.24, 4.15 and 4.61 orders of magnitude, respectively, that is, the number of bacteria is reduced from nearly 200 times to tens of thousands times.
[0112] 5.3 Time Effect
[0113] According to 2.1 in Example 2, clinical drug-resistant strain MRSA 12 samples were prepared and divided into 3 groups: M9 control group, antibiotic control group (200 μg / mL cefoperazone sodium sulbactam sodium), linoleic acid (1 mM) + antibiotic (200 μg / mL cefoperazone sodium sulbactam sodium) test group. Cultured at 37°C 200rpm, samples were taken every 2 hours within 12 hours, and the number of viable bacteria was detected by plate, and then converted into Log10 value. Each test sample was repeated 3 times. Results are shown in Figure 7 As shown in Figure C, the number of bacteria in the M9 control group remained basically stable within 12 hours; as time went on, the number of bacteria in the antibiotic group and the linoleic acid + antibiotic group gradually decreased; more importantly, at the same time point, the number of surviving bacteria in the linoleic acid + antibiotic group was significantly reduced compared with the number of surviving bacteria in the antibiotic group. And as time went on, the number of surviving bacteria decreased more significantly.
[0114] The details are as follows: After 2 hours, the number of surviving bacteria in the linoleic acid + antibiotic group decreased by 0.67 orders of magnitude, which means that the number of bacteria decreased by about 7 times. After 4-12 hours, the number of surviving bacteria in the linoleic acid + antibiotic group decreased by 1.21-2.96 orders of magnitude, which means that the number of bacteria decreased by about 10 to 1,000 times.
[0115] The above test results show that linoleic acid can cooperate with cefoperazone sodium and sulbactam sodium to improve the sensitivity of resistant Staphylococcus aureus to cefoperazone sodium and sulbactam sodium, and it has antibiotic concentration and linoleic acid concentration effects, as well as time effects.
[0116] Example 6 Linoleic acid synergistically with cefoperazone sodium and sulbactam sodium can improve the resistance of mice to clinical Staphylococcus aureus infection
[0117] 6.1 Linoleic acid synergistically with cefoperazone sodium and sulbactam sodium can improve the survival rate of mice infected with clinical Staphylococcus aureus
[0118] Taking Staphylococcus aureus as the representative of Gram-positive bacteria and cefoperazone sodium and sulbactam sodium as the representatives of antibiotics, the effect of linoleic acid combined with antibiotics was further explored.
[0119] Balb / c mice (6-8 weeks, about 20 grams, half male and half female) were divided into 4 groups, 16 in each group, namely, normal saline control group, antibiotic treatment group, linoleic acid test group, antibiotic + linoleic acid test group. The challenge strain was methicillin-resistant MRSA12, and the infection dose was 1.2×10 8 CFU, by intraperitoneal injection. One hour after bacterial infection of mice, mice in the antibiotic treatment group were given cefoperazone sodium and sulbactam sodium by intravenous injection at a dose of 200 mg / kg; mice in the linoleic acid experimental group were injected with linoleic acid by intraperitoneal injection at a dose of 200 mg / kg; mice in the antibiotic + linoleic acid experimental group were treated with antibiotics and linoleic acid according to their respective injection methods and doses. The death of mice was observed and recorded daily, and the survival rate of each group was calculated every day for a total of 7 days. The calculation formula is: Survival rate (%) = number of surviving mice in each group / total number of mice in each group × 100%.
[0120] The experimental results are shown in Figure 8 Figure A shows that in the saline control group, 81% died on the first day, and all died on the second day; in the antibiotic treatment group, 31% died on the first day, 62% died on the second day, and no more died thereafter, with a survival rate of 7%; in the linoleic acid test group, 7% died on the first day, 62% died on the second day, and 7% died on the third day, and then stabilized, no more died, and the survival rate was 24%. In the antibiotic + linoleic acid test group, no one died on the first day, 13% died on the second day, and then stabilized, no more died, and the survival rate was 87%.
[0121] The results showed that the protection rate of mice in the linoleic acid test group increased by 24% compared with the saline control group, and increased by 17% compared with the antibiotic treatment group. The protection rate of mice in the antibiotic + linoleic acid test group increased by 63% compared with the linoleic acid test group, and increased by 80% compared with the antibiotic treatment group. This shows that when mice are infected with methicillin-resistant bacteria, when antibiotic treatment is basically ineffective, linoleic acid can improve the resistance of mice to methicillin-resistant bacteria infection to a certain extent, but if linoleic acid and antibiotics are used in combination, the resistance of mice to methicillin-resistant bacteria infection is significantly improved.
[0122] 6.2 Linoleic acid synergistically with cefoperazone sodium and sulbactam sodium can improve the clearance of clinical Staphylococcus aureus infection in mice
[0123] Balb / c mice (6-8 weeks old, about 20 g, half male and half female) were divided into 4 groups, 6 mice in each group, namely, normal saline control group, antibiotic treatment group, linoleic acid test group, antibiotic + linoleic acid test group. The challenge strain was methicillin-resistant Staphylococcus aureus MRSA 12, and the infection dose was 1.4×10 6 CFU was measured by intraperitoneal injection. One hour after bacterial infection, mice in the antibiotic treatment group were intravenously injected with cefoperazone sodium and sulbactam sodium at a dose of 200 mg / kg; mice in the linoleic acid test group were intraperitoneally injected with linoleic acid at a dose of 200 mg / kg; mice in the antibiotic + linoleic acid test group were treated with antibiotics and linoleic acid according to their respective injection methods and doses. Six hours later, equal weight of viscera (liver, spleen, and kidney) were taken and fully ground, then diluted and plated, and the number of counts was counted.
[0124] Results Figure 8 Figure B shows that when mice are infected with drug-resistant bacteria, if they are treated with antibiotics, the bacterial loads in the spleen, kidney and liver of infected mice decrease by 55 times, 40 times and 33 times, respectively; if they are treated with linoleic acid, the bacterial loads in the spleen, kidney and liver of mice decrease by 20 times, 8 times and 17 times, respectively. If linoleic acid and antibiotics are treated, the bacterial loads in the spleen, kidney and liver of mice decrease by 136 times, 111 times and 97 times, respectively, compared with the antibiotic treatment group; and decrease by 51 times, 22 times and 50 times, respectively, compared with the linoleic acid test group. The results show that the combination of linoleic acid and antibiotics can significantly improve the clearance of clinical Staphylococcus aureus infection in mice.
[0125] Example 7 Linoleic acid increases bacterial membrane permeability, increases intracellular antibiotic penetration, and achieves antibiotic sensitivity
[0126] Taking Staphylococcus aureus as the representative of Gram-positive bacteria and cefoperazone sodium and sulbactam sodium as the representatives of antibiotics, the mechanism of improving the efficacy of linoleic acid combined with antibiotics was further explored.
[0127] 7.1 Exogenous linoleic acid can increase the permeability of bacterial membranes
[0128] Prepare bacteria according to 2.1 in Example 2, 9 strains of MSSA and 10 strains of MRSA. Each bacterial strain was divided into 2 groups, one group was a control group, and the other group was a linoleic acid (1mM) experimental group. Incubate at 37℃200rpm for 10 hours. Then take 100μL to 900μL M9 and add 2μL 2.5mM SYTO9 dye. Incubate at 37℃200rpm for 45 minutes, detect fluorescence by flow cytometry, and judge the change of membrane permeability by comparing the fluorescence intensity of the experimental group and the control group. The results are shown in Fig. 9As can be seen from the figure, the membrane permeability of both MSSA and MRSA is enhanced after exogenous addition of linoleic acid, which indicates that linoleic acid can improve the membrane permeability of bacteria.
[0129] 7.2 Exogenous linoleic acid can promote the entry of antibiotics into bacterial cells
[0130] The concentration of antibiotics entering bacterial cells is determined by detecting the inhibitory effect of antibiotics on microorganisms and calculating the activity (titer) of antibiotics.
[0131] Sample preparation for determination of intracellular antibiotic concentration of bacteria: MRSA 7 strain samples were prepared according to Example 2.1 and divided into 3 groups, namely, a control group without adding substances and antibiotics, a cefoperazone sodium sulbactam sodium group, and a cefoperazone sodium sulbactam sodium + linoleic acid group. Three biological replicates were performed in each group. The cells were cultured at 37°C and 200 rpm for 10 hours, and then the cells were collected by centrifugation and washed several times to clean the residual antibiotics in the culture medium. 1×M9 basic medium (containing 10 mM acetate, 1 M CaCl 2 ) Suspend the bacteria; adjust the bacterial solution to OD value of 1.0, collect 10 mL of bacterial solution by centrifugation. Add 350 μL of supersonication solution containing 2% SDS for ultrasonic disruption (supersonic disruption on ice, 35% supersonication power, 2s on, 3s off, ultrasonic disruption time of 25 min), centrifuge to obtain the supernatant, filter to remove the bacteria that may remain in the supernatant, and obtain the supersonication solution of the control group, cefoperazone sodium sulbactam sodium group, and cefoperazone sodium sulbactam sodium + linoleic acid group, respectively.
[0132] Preparation of test strains: Staphylococcus aureus ATCC17978 was cultured overnight to saturation and cultured in 1×M9 minimal medium (containing 10 mM acetate, 1 M CaCl 2 ) was diluted to OD600 of 0.2, and then diluted 10,000 times.
[0133] Standard curve drawing: Take 100 μL of the prepared test strain dilution and add 20 μL of cefoperazone sodium and sulbactam sodium to make the final concentrations 0, 10, 20, 40, 60, and 80 ng / mL, respectively. Mix the above samples and incubate them in a constant temperature shaker at 37°C and 200 rpm for 10 hours, and use a plate to detect the number of viable bacteria. Draw a standard curve with the number of bacterial cells as the ordinate and the antibiotic concentration as the abscissa.
[0134] Determination of bacterial intracellular antibiotic concentration: Take 100 μL of the prepared test strain dilution and add 20 μL of the prepared bacterial intracellular antibiotic samples, namely the super-ruptured liquid of the control group, the super-ruptured liquid of the cefoperazone sodium sulbactam sodium group, and the super-ruptured liquid of the cefoperazone sodium sulbactam sodium + linoleic acid group. After mixing, incubate at 37°C 200rpm for 10 hours, and use a plate to detect the number of viable bacteria. Then calculate the concentration of antibiotics in the sample according to the standard curve formula of cefoperazone sodium sulbactam sodium and bacterial count.
[0135] Results Fig.10 As shown in the figure, after adding linoleic acid on the basis of adding antibiotics, the amount of antibiotics entering the cells increased significantly. Compared with adding antibiotics alone, the amount of antibiotics entering the cells increased by 9.8 times after adding linoleic acid. The results show that linoleic acid can promote the amount of antibiotics entering bacterial cells.
[0136] The above test results show that after exogenous addition of linoleic acid, the bacterial cell membrane permeability increases, and the amount of antibiotics entering the bacterial cell increases. These indicate that linoleic acid increases the amount of antibiotics entering the cell by increasing the permeability of the bacterial membrane, thereby promoting the sensitivity of bacteria to antibiotics.
[0137] Example 8 Linoleic acid can delay the post antibiotic effect (PAE) of cefoperazone sodium and sulbactam sodium
[0138] Taking Staphylococcus aureus as the representative of Gram-positive bacteria and cefoperazone sodium and sulbactam sodium as the representatives of antibiotics, the effect of linoleic acid combined with antibiotics was further explored.
[0139] Three clinical strains, MSSA 2, MRSA 7 and MRSA12, were used as representatives. Single bacterial colonies were picked and placed in a 250 mL conical flask containing 50 mL LB, cultured overnight at 37 °C and 200 rpm, and then transferred to a 5 mL LB tube at a ratio of 1:100. When the bacteria grew to OD 600When the pH is 0.2, collect the bacteria by centrifugation and wash the bacteria three times with physiological saline. Resuspend the bacteria with 5 mL of MHB, and take 500 μL of the above bacterial solution and add it to a test tube containing 4.5 mL of MHB. Each strain is divided into 5 groups: MHB control group, 1×MIC SCF, 1×MIC SCF+1mM linoleic acid, 2×MIC SCF, 2×MIC SCF+1mM linoleic acid. There are 3 biological replicates for each treatment. Incubate at 37°C and 200 rpm for 2 hours. Take 100 μL of the above bacterial solution and dilute it 1000 times, then take 100 μL and add it to a 4.9 mL MHB test tube. Incubate the diluted bacterial solution at 37°C and 200 rpm, and take 100 μL of the bacterial solution at 0, 1, 2, 4, 6, 8, and 12 hours respectively. After dilution, use a plate to detect the number of viable bacteria. There are 3 biological replicates for all strains. Then take the time point as the horizontal axis and the average value of the logarithm of the corresponding colony number on the vertical axis to construct the bacterial growth curve.
[0140] PAE was then calculated from the bacterial growth curve using the following formula: PAE = TC, where T is the time required for the viable bacterial count in the test culture to increase by 1 Log10 CFU from the count observed immediately after dilution, and C is the corresponding time for the control group not exposed to the antibiotic. For this test, PAE (i.e., PAE) was calculated when SCF was added alone. SCF ), PAE with SCF+linoleic acid (PAE SCF+亚油酸 ), by comparing PAE SCF and PAE SCF+亚油酸 , to determine whether exogenous addition of linoleic acid would prolong the PAE of the antibiotic SCF.
[0141] The growth curve results were plotted as Fig.11 . Through further calculation, the PAE of the three strains after treatment with cefoperazone sodium and sulbactam sodium alone and linoleic acid + cefoperazone sodium and sulbactam sodium under the two conditions of 1×MIC and 2×MIC were obtained. The PAE of the cefoperazone sodium and sulbactam sodium antibiotic group, i.e., the SCF group, in the table is the result of comparison between the group with the addition of antibiotics and the control group; the PAE after treatment with linoleic acid + cefoperazone sodium and sulbactam sodium, i.e., SCF + linoleic acid, in the table is the result of comparison between the addition of linoleic acid + cefoperazone sodium and sulbactam sodium and the addition of antibiotics alone. The results are summarized in Table 5. The specific situation is detailed as follows:
[0142] Table 5 PAE of SCF and SCF+linoleic acid for 2 hours against 3 strains of Staphylococcus aureus (hours)
[0143]
[0144] For MSSA 2 strains, the PAE of cefoperazone sodium and sulbactam sodium at 1×MIC and 2×MIC were 0.15 and 2.11 hours, respectively. The PAE of SCF+linoleic acid was prolonged compared with the PAE of the antibiotic group, which was prolonged by 2.01 and 2.82 hours, respectively.
[0145] For MRSA 7 strains, the PAE of cefoperazone sodium and sulbactam sodium at 1×MIC and 2×MIC were 1.71 and 3.51 hours, respectively. The PAE of SCF+linoleic acid was prolonged compared with the PAE of the antibiotic group, which was prolonged by 3.44 and 4.06 hours, respectively.
[0146] For MRSA 12 strains, the PAE of cefoperazone sodium and sulbactam sodium at 1×MIC and 2×MIC were 0.96 and 1.04 hours, respectively. The PAE of SCF+linoleic acid was prolonged compared with the PAE of the antibiotic group, which was prolonged by 1.52 and 2.37 hours, respectively.
[0147] In general, linoleic acid can prolong the PAE of SCF, and the extension time varies among different strains.
[0148] The above embodiments are preferred implementation modes of the present invention, but the implementation modes of the present invention are not limited to the above embodiments. Any other changes, modifications, substitutions, combinations, and simplifications that do not deviate from the spirit and principles of the present invention should be equivalent replacement methods and are included in the protection scope of the present invention.
Claims
1. Application of linoleic acid in the preparation of antibiotic synergists, It is characterized in that The antibiotic is selected from cephalosporins, aminoglycosides, quinolones, tetracyclines, carbapenems, glycopeptides, macrolides, sulfonamides, penicillins or pharmaceutically acceptable salts thereof, or a compound preparation containing one or more of the antibiotics; and the penicillins do not include ampicillin.
2. The use according to claim 1, It is characterized in that The linoleic acid increases the sensitivity of Gram-positive bacteria to antibiotics.
3. Application of linoleic acid combined with antibiotics in the preparation of drugs for improving the sensitivity of Gram-positive bacteria to antibiotics. It is characterized in that The antibiotic is selected from cephalosporins, aminoglycosides, quinolones, tetracyclines, carbapenems, glycopeptides, macrolides, sulfonamides, penicillins or pharmaceutically acceptable salts thereof, or a compound preparation containing one or more of the antibiotics; and the penicillins do not include ampicillin.
4. Use of linoleic acid in combination with antibiotics in the preparation of drugs for preventing and / or treating Gram-positive bacterial infections, It is characterized in that The antibiotic is selected from cephalosporins, aminoglycosides, quinolones, tetracyclines, carbapenems, glycopeptides, macrolides, sulfonamides, penicillins or pharmaceutically acceptable salts thereof, or a compound preparation containing one or more of the antibiotics; and the penicillins do not include ampicillin.
5. The use according to any one of claims 1 to 4, It is characterized in that The antibiotic is selected from cefoperazone sodium, sulbactam sodium, cefotaxime, cefoperazone, amikacin, tobramycin, gentamicin, ofloxacin, levofloxacin, tetracycline, meropenem, vancomycin, azithromycin, sulfadiazine or amoxicillin sodium and clavulanate potassium.
6. The use according to any one of claims 2 to 4, It is characterized in that The Gram-positive bacteria are selected from one or more of Staphylococcus aureus, Streptococcus iniae, Streptococcus agalactiae, Streptococcus pyogenes, Bacillus subtilis, and Enterococcus faecalis.
7. A drug that increases the sensitivity of Gram-positive bacteria to antibiotics. It is characterized in that Contains an effective amount of linoleic acid and an antibiotic; the antibiotic is selected from cephalosporins, aminoglycosides, quinolones, tetracyclines, carbapenems, glycopeptides, macrolides, sulfonamides, penicillins or pharmaceutically acceptable salts thereof, or a compound preparation containing one or more of the antibiotics; and the penicillins do not include ampicillin.
8. The drug according to claim 7, It is characterized in that The antibiotic is selected from cefoperazone sodium, sulbactam sodium, cefotaxime, cefoperazone, amikacin, tobramycin, gentamicin, ofloxacin, levofloxacin, tetracycline, meropenem, vancomycin, azithromycin, sulfadiazine or amoxicillin sodium and clavulanate potassium.
9. The drug according to claim 7 or 8, It is characterized in that The mixing ratio of the linoleic acid and the antibiotic is 1: (2-40000) g / mol.
10. The drug according to claim 9, It is characterized in that The mixing ratio of the linoleic acid and the antibiotic is 1: (50-40000) g / mol.
Citation Information
Patent Citations
Synergist for improving gram-positive-bacterium-resistant effect of nisin
CN104605463A
Application of adenosine or adenosine monophosphate in preparation of anti-infective drugs
CN114159456A
Preparation for enhancement of action of anti-infective agent and method
CN1458847A
Pharmaceutical composition comprising a macrolide immunomodulator.
CN1764455A
Cited By
Application of valine in preparation of medicine for improving sensitivity of bacteria to antibiotics
CN119385997A
Use of linoleic acid in preparation of drug for improving sensitivity of gram-positive bacteria to antibiotic
WO2026026653A1
